QUANTITY | PRIC PER gr | SAVE AMOUNT |
---|---|---|
1 to 1 | EUR 20.00 /gr | 0% |
2 to 2 | EUR 17.00 /gr | 15% |
3 to 4 | EUR 13.00 /gr | 35% |
5 to 9 | EUR 11.00 /gr | 45% |
10 to 24 | EUR 9.00 /gr | 55% |
25 to 49 | EUR 8.00 /gr | 60% |
50 to 99 | EUR 7.00 /gr | 65% |
100 + | EUR 6.00 /gr | 70% |
POPULAR PRODUCT
Many customers bought this product recently.
Benzylpiperazine (BZP) is a synthetic compound that has gained attention for its use as a recreational drug, primarily due to its stimulant and euphoric effects. Research conducted over the years has indicated that the impact of BZP on users can be likened to that of amphetamines, although it requires a significantly higher dosage to achieve similar effects.
The compound was first created by Burroughs Wellcome & Company in 1944. Initially, it was believed to be synthesized for potential use as an antihelminthic agent aimed at treating parasitic infections in livestock. However, the interest in piperazines for this purpose came later, and much of the early research focused on their potential medicinal applications, particularly in the 1950s.
In the 1970s, BZP re-emerged in scientific literature as researchers explored its potential as an antidepressant. However, this line of inquiry was soon abandoned when studies revealed that BZP exhibited effects similar to those of amphetamines, raising concerns about its safety and efficacy.
BZP operates through a complex mechanism, influencing both serotonergic and dopaminergic systems, akin to the action of MDMA. It primarily affects the serotonin reuptake transporter, leading to increased serotonin levels in the synaptic cleft, which enhances the activation of serotonin receptors. While BZP shows some activity on the norepinephrine and dopamine transporters, its effects are less pronounced compared to its action on serotonin.
In terms of potency, studies have measured BZP's efficacy in releasing neurotransmitters, with values indicating a significant difference when compared to d-amphetamine and d-methamphetamine. Specifically, BZP's release metrics for dopamine, norepinephrine, and serotonin transporters suggest that while it shares some similarities with these substances, it requires a higher dosage to achieve comparable effects.
The subjective effects of BZP are often reported to be similar to those of traditional amphetamines. Notably, research has shown that individuals with a history of amphetamine use often find it challenging to differentiate between BZP and dextroamphetamine when administered intravenously, highlighting the compound's potent psychoactive properties.
Benzylpiperazine (BZP) Powder is for research use only and not intended for human consumption!
Benzylpiperazine (BZP) Powder stock last updated at: April 2025